[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].
To screen effective useful drugs for disease due to M. abscessus, we determined MIC of 3 cephems [ceftazidime (CAZ), cefoxitin (CFX), flomoxef (FMOX)] and 3 carbapenems [imipenem (IPM), panipenem (PAPM), meropenem (MEPM)] for 8 strains of clinically isolated M. abscessus by micro-dilution method using MGIT system. In all the 8 strains, MICs of CAZ are higher than 32 micrograms/ml. MIC50, MIC90, MIC range of CFX are 32 micrograms/ml, > 32 micrograms/ml and 16- > 32 micrograms/ml respectively, and for FMOX, 16 micrograms/ml, 32 micrograms/ml and 16-32 micrograms/ml; for IPM, 8 micrograms/ml, 16 micrograms/ml and 8-16 micrograms/ml; for PAPM, 4 micrograms/ml, 16 micrograms/ml and 4-16 micrograms/ml; for MEPM, 8 micrograms/ml, 16 micrograms/ml and 8-16 micrograms/ml. From this study, it is concluded that FMOX, IPM, PAPM and MEPM can be clinically useful drugs in the treatment of the disease due to M. abscessus.
Research Division, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama, Kiyose-shi, Tokyo 204-8533, Japan. ito@jata.or.jp
Kunihiko
K
Ito
Kenichi
K
Hashimoto
Hideo
H
Ogata
D015780:Carbapenems / Q000494:pharmacology*; D002440:Cefoxitin / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests / Q000379:methods; D009165:Mycobacterium Infections, Nontuberculous / Q000382:microbiology; D016926:Mycobacterium chelonae / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000382:microbiology
D015780:Carbapenems; D002511:Cephalosporins; D013845:Thienamycins; D002440:Cefoxitin; D015378:Imipenem; D002442:Ceftazidime; D000077731:Meropenem; C045693:flomoxef; C039536:panipenem